Magnetic resonance spectroscopy in cancer: Phospholipid, neutral lipid and lipoprotein metabolism and function

Anticancer Research

Volumn 16, Issue 3 B, 1996, Pages 1305-1315

  Podo, Franca ^a   De Certaines, Jacques D ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Cancer Institute Eugène Marquis   (France)

Author keywords

Lipoproteins; MRS; MRSI; Neutral lipids; Phospholipids

Indexed keywords

LIPOPROTEIN; PHOSPHOLIPID;

CANCER CELL; CELL FUNCTION; CONFERENCE PAPER; ENERGY METABOLISM; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

HUMANS; LIPID METABOLISM; LIPOPROTEINS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; PHOSPHOLIPIDS;

EID: 0030037464     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Mountford CE. Mackinnon WB, Russell P, Rutter A, Delikatny EJ: Human cancers detected by proton MRS and chemical shift imaging ex vivo. Anticancer Res 16: 1521-1532, 1996.
2. 31P NMR using surface coils. Nature 283: 167-170, 1980.
3. 31P NMR studies of human tumor in situ. Lancet 1: 1435-1436, 1983.
4. Odeblad E: Department of medical research with NMR. Acta Isotopica 1: 27-83, 1961.
5. Fossel ET, Carr JM, Mc Donagh J: Detection of malignant tumours: water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. New Engl J Med 315: 1369-1376, 1986.
6. Vance JE, Shiao Y-J: Intracellular trafficking of phospholipids. Anticancer Res 16: 1333-1340, 1996.
7. Negendank W: Studies of human tumors by MRS: a review. NMR Biomed 5: 303-324, 1992.
8. 31P MRS of experimental tumours. NMR Biomed 6: 345-365, 1993.
9. Cross KJ, Holmes KT, Mountford CE and Wright PE: Assignment of acyl chain resonances from membranes of mammalian cells by two-dimensional NMR methods. Biochemistry 23: 5895-5897, 1984.
10. Freitas I, Pontiggia P, Barni S, Bertone V, Parente M, Novarina A, Roveta G, Gerzeli G, and Stoward PJ: Histochemical probes for the detection of hypoxic cells. Anticancer Res 10: 611-620, 1990.
11. Hirakawa T, Maruyama K, Kohl NE, Kodama T and Ruley HE: Massive accumulation of neutral lipids in cells conditionally transformed by an activated H-ras oncogene, Oncogene 6: 289-295, 1991.
12. Massarelli R, Remy C, Sam Lai E, Fouillé N, Barba I, Ziegler A, Décorps M and Arús C: Subcellular localisation and identification of the lipid resonance at 1.3 ppm in rat intracerebral tumors. Anticancer Res 15 (5A): p. 1704 (Abstract 197), 1995.
13. Poste G and Nicholson GL: Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. Proc. Natl Acad Sci US 77: 399-403, 1980.
14. Aiken NR, Gillies RG: Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. Anticancer Res 16: 1393-1398, 1996.
15. Smith TAD, Eccles S, Box G, Titley JC, Leach MO, McCready VR: Phosphocholine and choline content of rat sarcoma cells grown in the presence and absence of serum. Anticancer Res 16: 1389-1392, 1996.
16. 31P NMR spectroscopy. Anticancer Res 16: 1357-1364, 1996.
17. 31P MRS of human tumor cells: effects of culture media and conditions on phospholipid metabolite concentrations. Anticancer Res 16: 1365-1374, 1996.
18. Katz-Brull R, Degani H: Kinetics of choline transport and phosphorylation in human breast cancer cells: NMR application of the zero trans method. Anticancer Res 16: 1375-1380, 1996.
19. 31C NMR study. Anticancer Res 16: 1351-1356, 1996.
20. Vance DE, Houweling M, Lee M, Cui Z: Phosphatidylethanolamine methylation and hepatoma cell growth. Anticancer Res 16: 1413-1416, 1996.
21. Ting Y-LT, Sherr D, Degani H: Variations in the energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res 16: 1381-1388, 1996.
22. Pelech SL and Vance D: Signal transduction via phosphatidylcholine cycles. TIBS 14: 28-30, 1989.
23. Lacal JC, Moscat J and Aaronson SA: Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-ras oncogene. Nature 330: 269-272, 1987.
24. Moscat J, Cornet ME, Diaz-Meco MT, Larrodera P, Lopez-Alanon D and Lopez-Barahona M: Activation of phosphatidylcholine-specific phospholipase C in cell oncogene transformation. Biochem Soc Trans 17: 988-991, 1989.
25. Ferretti A, Podo F, Carpinelli G, Chen LL, Borghi P, and Masella R: Detection of neutral active phosphatidylcholine-specific phospholipase C in Friend leukemia cells before and after erythroid differentiation. Anticancer Res 13: 2309-2318, 1993.
26. Podo F, Ferretti A, Knijn A, Zhang PJ, Ramoni C, Pini C, Baccarini S, Pulciani S: Detection of phosphatidylcholine-specific phospholipase C in 3T3 fibroblasts and their H-ras transformants. NMR and immunochemical studies. Anticancer Res 16: 1399-1412, 1996.
27. Corda D, Falasca M: Glycerophosphoinositols as potential markers of ras-induced transformation and novel second messengers. Anticancer Res 16: 1341-1350, 1996.
28. Cantafora A, Blotta I: Neutral lipids production, transport, utilization. Anticancer Res 16: 1441-1450, 1996.
29. de Certaines JD, Nadal L, Leray G, Serrai H, Lewa CJ: Proton nuclear magnetic resonance spectroscopy of plasma lipoproteins: technical problems and potential interest in cancer disease. Anticancer Res 16: 1451-1460, 1996.
30. Engan T: Magnetic resonance spectroscopy of blood plasma in malignant disease: methodological aspects and clinical relevance. Anticancer Res 16: 1461-1472, 1996.
31. 1H nuclear magnetic resonance spectroscopy data from human plasma. Anticancer Res 16: 1473-1478, 1996.
32. 13C NMR spectroscopy of lipids: a simple method for absolute quantitation. Anticancer Res 16: 1479-1484, 1996.
33. Leray G, de Certaines J: Proton NMR spectroscopy of plasma lipoproteins: a marker of immune function in cancer disease? Anticancer Res 14: 1839-1852, 1994.
34. Henke J, Willker W, Engelmann J, Leibfritz D: Combined extraction techniques of tumour cells and lipid/phospholipid assignment by two dimensional NMR spectroscopy. Anticancer Res 16: 1417-1428, 1996.
35. Engelmann J, Henke J, Willker W, Kutscher B, Nößner G, Leibfritz D: Early stage monitoring of miltefosine apoptosis in KB cells by multinuclear NMR spectroscopy. Anticancer Res 16: 1429-1440, 1996.
36. Kuesel AC, Briere KM, Halliday WC, Sutherland GR, Donnelly SM. Smith ICP: Mobile lipid accumulation in necrotic tissue of high grade astrocytomas. Anticancer Res 16: 1485-1490, 1996.
37. Freitas I, Bono B, Bertone V, Griffini P, Baronzio GF, Bonandrini L, Gerzeli G: Characterization of the metabolism of perinecrotic cells in solid tumors by enzyme histochemistry. Anticancer Res 16: 1491-1502, 1996.
38. Leach MO: Introduction to in vivo MRS of cancer: new perspectives and open problems. Anticancer Res 16: 1503-1514, 1996.
39. Bovée WMMJ, Karlsen OT, Rozijn TH: Spatial resolution and spectral information content of proton NMR spectroscopic imaging of tumour metabolism. Anticancer Res 16: 1515-1520, 1996.
40. 31P MRS in vivo in human cancer: implications for experimental models and clinical studies. Anticancer Res 16: 1533-1538, 1996.
41. 1H MRS in vivo in brain tumors: experience of the Siemens cooperative clinical trial. Anticancer Res 16: 1539-1544, 1996.
42. Gotsis ED, Fountas K, Kapsalaki E, Toulas P, Periasteris G, Papadakis N: In vivo proton MR spectroscopy: the diagnostic possibilities of lipid resonances in brain tumors. Anticancer Res 16: 1565-1568, 1996.
43. 1H Magnetic Resonance Spectroscopy of colon tissue. Anticancer Res 16: 1553-1558, 1996.
44. 1H spectroscopy of bone marrow during therapy of leukemia. Anticancer Res 16: 1545-1552, 1996.
45. Schick F, Duda SH, Lutz O, Claussen CD: Lipids in bone tumors assessed by Magnetic Resonance: chemical shift imaging and proton spectroscopy in vivo. Anticancer Res 16: 1569-1574, 1996.
46. 1H-spectroscopy. Anticancer Res 16: 1581-1586, 1996.
47. 1H MRS analysis of human brain tumors. Anticancer Res 16: 1559-1564, 1996.
48. 31P NMR spectroscopy in clinical analysis of changes of sera phospholipids in haematological and other cancer diseases. Anticancer Res 16: 1587-1594, 1996.
49. Linder-Horowitz H, Knox WE, Morris HP: Glutaminase activities and growth rates of rat hepatomas. Cancer Res 29: 1195-1199, 1969.
50. +- malic enzyme of tumor mitochondria. J Biol Chem 259: 6222-6227, 1984.
51. 2 ratios. Biochem J 246: 633-639, 1987.
52. Lavietes BB, Coleman PJ: The role of lipid metabolism in neoplastic differentiation. J Theor Biol 85: 523-542, 1980.
53. Gooridge A: Regulation of the activity of acetylcoenzyme A carboxylase by palmitoyl coenzyme A and citrate. J Biol Chem 247: 6946-6956, 1972.
54. Sabine JR: Metabolic controls in precancerous liver. VII. Time courses of loss of dietary feedback control of cholesterol synthesis during carcinogen treatment. Eur J Cancer 12: 299-303, 1976.
55. Schroeder K, Kier AB, Olson CD, Dempsey ME: Correlation of tumor metastasis with sterol carrier protein and plasma membrane sterol levels. Biochem Biophys Res Commun 124: 283-289, 1984.
56. Lyons HT, Karroubi A, Wolins N, Tenner S, Chanderbahn RF, Fiskum G, Donaldson RP: Elevated cholesterol and decreased sterol carrier protein-2 in peroxisomes from AS30-D hepatoma compared to normal rat liver. Arch Biochem Biophys 285: 238-245, 1991.
57. Dessi S, Batetta B, Anchisi C, Pani P, Broccia G, Tessitore L, Costelli P, Baccino FM: Cholesterol metabolism in normal and neoplastic cell proliferation. Arch Gerontol Geriatr Suppl 2: 563-568, 1991